Results 121 to 130 of about 636,644 (329)

Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker Validation Study

Aging, 2013
A minimally invasive test for early detection and monitoring of Alzheimer's and other neurodegenerative diseases is a highly unmet need for drug development and planning of patient care. Mild Cognitive Impairment (MCI) is a syndrome characteristic of early stages of many neurodegenerative diseases.
Kira S, Sheinerman, Vladimir G, Tsivinsky, Laila, Abdullah, Fiona, Crawford, Samuil R, Umansky   +4 more
openaire   +2 more sources

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Racial and ethnic differences in plasma p‐tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Consistent predictive performance across racial and ethnic groups is essential to the use of plasma biomarkers as screening tools in preclinical Alzheimer's disease trials.
Doris P. Molina‐Henry, Rema Raman, Andy Liu, Oliver Langford, Joel B. Braunstein, Philip B. Verghese, Venky Venkatesh, Shobha Dhadda, Michael Irrizary, Joshua D. Grill, Keith Johnson, Robert A. Rissman, Paul Aisen, Reisa A. Sperling, AHEAD 3‐45 Study Team   +14 more
doaj   +1 more source

Physical Activity, Alzheimer Plasma Biomarkers, and Cognition

JAMA Network Open
ImportancePhysical activity (PA) is a nonpharmacological intervention for dementia prevention. The association between PA and Alzheimer disease (AD) plasma biomarkers remains underexplored.ObjectiveTo investigate the associations among PA; plasma biomarkers, including β-amyloid 42/40 (Aβ42/40), phosphorylated-tau217 (ptau217), glial fibrillary acidic ...
Seung Ae Kim, Daeun Shin, Hongki Ham, Yeshin Kim, Yuna Gu, Hee Jin Kim, Duk L. Na, Henrik Zetterberg, Kaj Blennow, Sang Won Seo, Hyemin Jang, Sang Won Seo, Duk L. Na, Hyemin Jang, Youngsoo Kim, Sun-Ho Han, JoonKyung Seong, Jun-Kyu Choi, Eek-Sung Lee, Juhee Chin, Chi-Hun Kim, Hee Jin Kim, Haesook Bok, Sung Hoon Kang, Yeshin Kim, Si Eun Kim, Hang-Rai Kim, Na-Yeon Jung, Seung Joo Kim, Seunghee Na, Geon Ha Kim, Ko Woon Kim, Jin San Lee, Hanna Cho, Yeo Jin Kim, Soo Hyun Cho, Byeong C. Kim, Dong Young Lee, So Young Moon, Min Soo Byun, Giijung Jung, Dahyun Yi, Han Na Lee, Jae-Won Jang, Jee Hyang Jeong, Young Hee Jung, Jong Hun Kim, Young Noh, Hyunjung Yang, Youngji Ha, Hae-Eun Shin, Kyunghun Kang, SungHui Eom, Ki Young Shin, Yeongshin Kim, Jisung Jang, Changsik Yoon, Do kyung Lee, Hongki Ham, Yu Hyun Park, Soo-Jong Kim, Byunghyun Byun, Yejoo Choi, Na Kyung Lee, Hong-Hee Won, Minyoung Cho, Sang-Hyuk Jung, Dong Hyun Lee, Beomsu Kim, Jinkyu Seo, Bo Kyoung Cheon, Youngju Kim   +71 more
openaire   +2 more sources

Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke: A Multicenter Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai, Yang Qu, Reziya Abuduxukuer, Kejia Zhang, Peng Zhang, Xin Tang, Huaimei Zhang, Lijuan Wang, Lichong Yang, Shuangxu Tan, Zhimei Yuan, Ce Han, Lili He, Yuping Zheng, Fenglan Zhao, Lijie Guo, Ligang Jiang, Jinfeng Li, Yongfei Jiang, Xuexia Zou, Dan Xu, Han Xu, Xiaojia Wang, Yingbin Qi, Xuefeng Hu, Yu Zhang, Zhen‐Ni Guo, Hang Jin, on behalf of the Biomarkers of Brain Injury Investigator Study Group   +28 more
wiley   +1 more source

A novel pan‐cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic [PDF]

, 2019
Wei Liu, Jie Li, Ping Zhang, Qiaoyun Hou, Feng Shi, Lisheng Liu, Dawei Cui, Hubing Shi, Yan Fu, Yongzhang Luo   +9 more
openalex   +1 more source

Supplementary Table from Plasma miR-151-3p as a Candidate Diagnostic Biomarker for Head and Neck Cancer: A Cross-sectional Study within the INHANCE Consortium

, 2023
Roberta Pastorino, Michele Sassano, Francesco Danilo Tiziano, Luca Giraldi, Rosarita Amore, Dario Arzani, Emanuela Abiusi, Wolfgang Ahrens, Laia Alemany, Cristina Canova, Claire M. Healy, Ivana Holcátová, Παγώνα Λάγιου, Jerry Polesel, Maja Popović, Ståle Nygård, Gabriella Cadoni, Ariana Znaor, Paolo Boffetta, Keitaro Matsuo, Isao Oze, Paul Brennan, Stefania Boccia   +22 more
openalex   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source